AUTH/2037/8/07 - Pharmaceutical adviser at a PCT v Teva

Promotion of Qvar

  • Received
    17 August 2007
  • Case number
    AUTH/2037/8/07
  • Applicable Code year
    2006
  • Completed
    30 October 2007
  • Breach Clause(s)
    7.2
  • Sanctions applied
    Undertaking received
  • Additional sanctions
  • Appeal
    No appeal
  • Review
    Published in the February 2007 Review

Case Summary

The pharmaceutical adviser to a primary care trust (PCT) complained about what had been said by the medical director of Teva at an educational meeting organised by the company. Teva marketed Qvar, a CFC-free beclometasone (BDP) inhaler.

The complainant noted that the discontinuation of Becotide (BDP inhaler) by GlaxoSmithKline and the planned phasing out of CFC-containing BDP inhalers had caused a number of problems in recent months. The launch of Clenil Modulite by Trinity-Chiesi the second CFC-free BDP inhaler on the market had further escalated this problem.

The complainant stated that the problems were currently; the lack of guidance and information of when CFC-BDP would cease to be available, there was no clear guidance of when to switch to CFC-free BDP inhalers; the potency difference between Qvar and Clenil Modulite. Qvar was approximately twice as potent as Clenil and thus CFC-free prescribing required prescribing by brand (it was potentially hazardous if patients received the wrong inhaler); the fact that Qvar was not licensed for use in children under 12 years of age.

The complainant was concerned that at the meeting Teva's medical director had emphasised the following: a requirement to switch to CFC-free BDP due to the phase out of Becotide/Becloforte (this was not currently a requirement) and that there was now no choice but to switch to Qvar or Clenil. This was inaccurate as generic CFC-BDP was still available.

However, the speaker had not referred to the continued availability of generic CFC-BDP, which was quite clearly still a treatment option for patients, or the fact that Qvar was not licensed for use in children. This was a concern when the company was encouraging a therapeutic switch.

The complainant alleged that it was inappropriate and potentially hazardous to patients for a company to encourage a switch to its product when the meeting was advertised as an educational meeting. It was also inappropriate and potentially hazardous to patients, for a company to encourage a switch to a product without highlighting the licensing limitations for children. In response to a question about the licensing, the medical director stated that the issue was with the Medicines and Healthcare products Regulatory Agency (MHRA) and would be licensed imminently. This was speculation and by no means guaranteed, and such information should not be shared in a meeting of health professionals; such a forum should be for factual information and not speculation.

The complainant stated that in response to a question about generic CFC-BDP, the medical director explained that he was unsure of the continued availability of CFC gases and that he did not believe that supplies would exceed 12 months. He also actively discouraged this course of action, which again was inappropriate for this forum. Teva currently marketed CFC-BDP inhalers and the medical director should be in a better position to provide all the information that was required of him, as opposed to providing information that was favourable for the promotion of Qvar. Any discontinuation of a product should require a minimum notice period.

The Panel noted that at the meeting at issue, 'How to Improve Asthma in General Practice', the title of the medical director's presentation was 'Implications of the CFC phase out and the introduction of Beclomethasone CFC Free Alternatives'. The Panel did not accept Teva's submission that the presentation was not promotional. In the Panel's view, although there was an educational content it nonetheless promoted Qvar.

The Panel noted Teva's submission regarding the continued availability of generic CFC-BDP which, although a theoretical possibility, did not appear to be a long-term practical solution to the discontinuation of Becotide/Becloforte. According to Teva no company had applied for a CFC gas allocation in 2008 and so CFC-BDP was expected to be exhausted sooner rather than later. In any event, Teva had submitted that it was unlikely that the current manufacturers of CFC-BDP would be able to fill the gap left by Becotide/Becloforte. Clinicians had no choice but to eventually switch to CFC-free BDP. There was no set date when CFC-BDP would no longer be available. The Panel considered that, in the context of a presentation about the implications of CFC phase out, it was not necessarily misleading to encourage health professionals to plan ahead for a time when CFC-BDP would no longer be available. No breach of the Code was ruled.

The Panel noted that the medical director did not state in his presentation that, unlike Becotide, Qvar was not licensed for use in children under 12. Although, according to Teva, less than 15% of asthmatics were under 12 years of age, this group would nonetheless present clinicians with important practical and clinical considerations as they planned to switch patients to CFC-free BDP. In that regard the Panel considered that, in the context of the presentation at issue, the omission of such information was misleading. A breach of the Code was ruled.

According to the complainant, he had asked the medical director about the use of Qvar in children and received the reply that the issue was with the MHRA and the product would be so licensed imminently. Teva submitted that the medical director had referred to the need to conduct a growth study and that results from that would not be due until the second half of 2008 and following this a paediatric licence would be expected in a short period of time. When asked for more information the medical director had stated that the timing of the regulatory process was not something that could be shared. The medical director had stated that Teva anticipated a successful application process with appropriate timings as Qvar was licensed for use in children in 10 European countries. Nonetheless, the Panel noted that its ruling above that it was misleading not to mention that Qvar was not licensed for children below the age of 12.

The Panel was concerned that the complainant appeared to have been left with the impression that the change in licence to allow paediatric use was imminent. Teva had submitted that it expected the licence to be granted shortly after the completion of the paediatric growth study which was due in the second half of 2008. There appeared to be a difference of opinion.

The answer given to the complainant was in response to an unsolicited enquiry. There was no evidence to show that on the balance of probabilities the answer was not factual and accurate, or that it was either misleading or promotional. The answer could thus take advantage of one of the exclusions to promotion. The Panel did not consider that in this regard Qvar had been promoted for use in children. No breach of the Code was ruled.